Gyeonggi, South Korea

Hyoung-Jun Pae

This inventor holds 1 USPTO granted patent. Top assignee: Hanmi Pharmaceutical Co., Ltd.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyoung-Jun Pae. Retrieved from https://idiyas.com/inventor/hyoung-jun-pae

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hyoung-Jun Pae: Innovator in Erythromycin A Compounds

Introduction

Hyoung-Jun Pae is a notable inventor based in Kyunggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of erythromycin A compounds. His innovative work has led to the creation of a new compound that holds promise for medical applications.

Latest Patents

Hyoung-Jun Pae holds 1 patent for his invention titled "Erythromycin A Compounds and Process for Preparing the Same." This patent describes a new erythromycin A 9-oxime compound that can be effectively used as intermediates for the preparation of erythromycin A oxime compounds. The process outlined in the patent also details how to prepare 6-O-alkyl erythromycin A or its oxime using the newly developed compound.

Career Highlights

Hyoung-Jun Pae is currently employed at Hanmi Pharmaceutical Co., Ltd., a leading company in the pharmaceutical industry. His work at Hanmi has allowed him to focus on innovative research and development in the field of antibiotics.

Collaborations

Hyoung-Jun Pae has collaborated with notable colleagues, including Kwee-Hyun Suh and Nam-Du Kim. These collaborations have contributed to the advancement of research in the pharmaceutical sector.

Conclusion

Hyoung-Jun Pae's contributions to the field of erythromycin A compounds exemplify the impact of innovative research in pharmaceuticals. His work continues to influence the development of new medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…